FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, Jul 18, 2025
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on July 18, 2025, issued by the New Jersey District Office, covering biologics.
View Company Profile
ID · e6f01d89-0a13-4fb3-a74e-dfb41429a3bc
Inspection Facts
- Inspection number
- 1275526
- FDA center
- Biologics
Other FDA inspections of Bristol-Myers Squibb Company
16| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2026 | Not classified | New Jersey District Office | |
| December 6, 2024 | VAI | New Jersey District Office | Postmarketing Surveillance and Epidemiology: Human Drugs |
| September 6, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| January 31, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| June 16, 2023 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1327472 - 2026-06-23
- FDA Inspection 1236864 - 2024-12-06
- FDA Inspection 1247735 - 2024-09-06
- FDA Inspection 1228973 - 2024-01-31
- FDA Inspection 1208871 - 2023-06-16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.